Levalbuterol Soln Neb — $0 on Listed Strengths
Levalbuterol Soln Neb is $0 on listed strengths only. Other strengths are not a blanket $0.
Levalbuterol Soln Neb Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | $0 on listed strengths |
| Typical Retail | $183.00 |
$0 on listed strengths: 0.63mg/3ml Inhalation (max 225); 1.25mg/3ml Inhalation (max 225)
About Levalbuterol Soln Neb
Levalbuterol Soln Neb is a prescription medication. Ask your doctor if Levalbuterol Soln Neb is right for you.
Other strengths and forms of Levalbuterol
Conditions Treated with Levalbuterol Soln Neb
- Asthma (bronchospasm)
- Bronchiolitis
- Bronchiolitis (symptomatic)
- COPD (bronchospasm)
- Exercise‑induced bronchospasm
- Hyperkalemia (nebulized adjunct)
How to Check Levalbuterol Soln Neb Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available membership pricing
Levalbuterol Soln Neb at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
What Levalbuterol Soln Neb is approved for (FDA label)
Levalbuterol Inhalation Solution, USP is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. Levalbuterol Inhalation Solution, USP is a beta 2 -adrenergic agonist indicated for: Treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. ( 1 )
Source: Read the full FDA label on DailyMed. Label effective date: August 11, 2026.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Dosage forms and strengths for Levalbuterol Soln Neb (FDA label)
Inhalation Solution 3 mL unit-dose, vials in three dosage strengths of levalbuterol; 0.31 mg, 0.63 mg, 1.25 mg. Each strength of Levalbuterol Inhalation Solution, USP is available in a shelf carton containing one or more foil pouches, each pouch containing one or more unit-dose vials. Inhalation Solution (unit-dose vial for nebulization): 0.31 mg/3 mL, 0.63 mg/3 mL and 1.25 mg/3 mL. ( 3 )
Source: FDA prescribing information (DailyMed). Set ID: 58beb877-b94a-bbe0-e063-6294a90a7fe0. SPL document ID: 58beb881-4ab1-60f1-e063-6394a90a3470. Label effective date: August 11, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Levalbuterol Soln Neb (FDA label)
The following serious adverse reactions are described below and elsewhere in the labeling: Paradoxical bronchospasm [see Warnings and Precautions ( 5.1) ] Cardiovascular effects [see Warnings and Precautions ( 5.4 ) ] Immediate hypersensitivity reactions [see Warnings and Precautions ( 5.6 ) ] Hypokalemia [see Warnings and Precautions ( 5.8 ) ] Most common adverse reactions are: palpitations, chest pain, tachycardia, headache, dizziness, tremor and nervousness. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact The Ritedose Corporation, LLC at 1-855-806-3300 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of the drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Source: FDA prescribing information (DailyMed). Set ID: 58beb877-b94a-bbe0-e063-6294a90a7fe0. SPL document ID: 58beb881-4ab1-60f1-e063-6394a90a3470. Label effective date: August 11, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Levalbuterol Soln Neb (FDA label)
Levalbuterol Inhalation Solution, USP is contraindicated in patients with a history of hypersensitivity to levalbuterol or racemic albuterol. Reactions have included urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema [see Warnings and Precautions ( 5.6 ) ]. Hypersensitivity to levalbuterol or racemic albuterol. ( 4 )
Source: FDA prescribing information (DailyMed). Set ID: 58beb877-b94a-bbe0-e063-6294a90a7fe0. SPL document ID: 58beb881-4ab1-60f1-e063-6394a90a3470. Label effective date: August 11, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Warnings and precautions for Levalbuterol Soln Neb (FDA label)
Life-threatening paradoxical bronchospasm may occur. Discontinue Levalbuterol Inhalation Solution, USP immediately and treat with alternative therapy. ( 5.1 ) Need for more doses of Levalbuterol Inhalation Solution, USP than usual may be a sign of deterioration of asthma and requires reevaluation of treatment. ( 5.2 ) Levalbuterol Inhalation Solution, USP is not a substitute for corticosteroids. ( 5.3 ) Cardiovascular effects may occur. Consider discontinuation of Levalbuterol Inhalation Solution, USP if these effects occur. Use with caution in patients with underlying cardiovascular disorders. ( 5.4 ) Excessive use may be fatal. Do not exceed recommended dose. ( 5.5 ) Immediate hypersensitivity reactions may occur. Discontinue Levalbuterol Inhalation Solution, USP immediately. ( 5.6 ) Hypokalemia and changes in blood glucose may occur. ( 5.7 , 5.8 ) 5.1 Paradoxical Bronchospasm Levalbuterol Inhalation Solution, USP can produce paradoxical bronchospasm, which may be life-threatening.
Source: FDA prescribing information (DailyMed). Set ID: 58beb877-b94a-bbe0-e063-6294a90a7fe0. SPL document ID: 58beb881-4ab1-60f1-e063-6394a90a3470. Label effective date: August 11, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Drug interactions for Levalbuterol Soln Neb (FDA label)
Other short-acting sympathomimetic aerosol bronchodilators and adrenergic drugs: May potentiate effect. ( 7.1 ) Beta-blockers: May block bronchodilatory effects of beta-agonists and produce severe bronchospasm. Patients with asthma should not normally be treated with beta-blockers. ( 7.2 ) Diuretic: May worsen electrocardiographic changes or hypokalemia associated with diuretic may worsen. Consider monitoring potassium levels. ( 7.3 ) Digoxin: May decrease serum digoxin levels.
Source: FDA prescribing information (DailyMed). Set ID: 58beb877-b94a-bbe0-e063-6294a90a7fe0. SPL document ID: 58beb881-4ab1-60f1-e063-6394a90a3470. Label effective date: August 11, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.